{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:26:52Z","timestamp":1787020012525,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Chinese Ministry of Science and Technology Innovation Fund for small and medium enterprises","award":["Project code: 13CR6R16105758"],"award-info":[{"award-number":["Project code: 13CR6R16105758"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ropivacaine oil delivery depot (RODD) can be used to treat postoperative incision pain. The aim was to study pharmacodynamics, toxicity and toxicokinetics of RODD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The base research of RODD were conducted. Thirty rabbits were randomly divided into saline, solvent, ropivacaine aqueous injection (RAI) 0.9\u00a0mg, RODD 0.9\u00a0mg and RODD 3\u00a0mg groups. The sciatic nerve of rabbits were isolated, dripped with RODD and the effect of nerve block were observed. In toxicity study, the rats were divided into saline, solvent and RODD 75, 150 and 300\u00a0mg\/kg groups, 30 rats per group. In toxicokinetics, rats were divided into RODD 75, 150 and 300\u00a0mg\/kg groups, 18 rats per group. The rats were subcutaneously injected drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analgesic duration of RODD 3\u00a0mg and RAI 0.9\u00a0mg blocking ischiadic nerve lasted about 20\u00a0h and 2\u00a0h, respectively, and their blocking intensity was similar. The rats in RODD 75\u00a0mg\/kg did not show any toxicity. Compared with saline group, in RODD 150\u00a0mg\/kg group neutrophils and mononuclear cells increased, lymphocytes decreased and albumin decreased(\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), and pathological examination showed some abnormals. In RODD 300\u00a0mg\/kg group, 10 rats died and showed some abnormalities in central nerve system, hematologic indexes, part of biochemical indexes, and the weights of spleen, liver, and thymus. However, these abnormal was largely recovered on 14\u00a0days after the dosing. The results of toxicokinetics of RODD 75\u00a0mg\/kg group showed that the C\n                      <jats:sub>max<\/jats:sub>\n                      was 1.24\u2009\u00b1\u20090.59\u00a0\u00b5g\/mL and the AUC\n                      <jats:sub>(0-24\u00a0h)<\/jats:sub>\n                      was 11.65\u2009\u00b1\u20091.58\u00a0h\u00b7\u00b5g\/mL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Subcutaneous injection RODD releases ropivacaine slowly, and shows a stable and longer analgesic effect with a large safety range.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12871-022-01653-1","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T06:04:34Z","timestamp":1650521074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacodynamics, toxicology and toxicokinetics of ropivacaine oil delivery depot"],"prefix":"10.1186","volume":"22","author":[{"given":"Wu-dang","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-quan","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-liang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-xiao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"1653_CR1","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.3892\/etm.2016.3807","volume":"12","author":"R Dong","year":"2016","unstructured":"Dong R, Yu BW, Chen LJ, Yu WF. The 5-HT2A receptor potassium-chloride cotransporter 2 signaling pathway in a rat incision pain model. Exp Ther Med. 2016;12:3583\u20138. https:\/\/doi.org\/10.3892\/etm.2016.3807.","journal-title":"Exp Ther Med"},{"key":"1653_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/AJP.0b013e31816b2f43","volume":"24","author":"LF Chu","year":"2008","unstructured":"Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008;24:479\u201396. https:\/\/doi.org\/10.1097\/AJP.0b013e31816b2f43.","journal-title":"Clin J Pain"},{"key":"1653_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.phrs.2017.02.012","volume":"120","author":"AA Weinbroum","year":"2017","unstructured":"Weinbroum AA. Postoperative hyperalgesia-a clinically applicable narrative review. Pharmacol Res. 2017;120:188\u2013205. https:\/\/doi.org\/10.1016\/j.phrs.2017.02.012.","journal-title":"Pharmacol Res"},{"key":"1653_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1744806917718753","volume":"13","author":"F Xing","year":"2017","unstructured":"Xing F, Kong C, Bai L, Qian J, Yuan J, Li Z, Zhang W, Xu JT. CXCL12\/CXCR4 signaling mediated ERK1\/2 activation in spinal cord contributes to the pathogenesis of postsurgical pain in rats. Mol Pain. 2017;13:1\u201312. https:\/\/doi.org\/10.1177\/1744806917718753.","journal-title":"Mol Pain"},{"key":"1653_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3969\/j.issn.1006-9852.2018.05.011","volume":"5","author":"Q Wan","year":"2018","unstructured":"Wan Q, Xue QS, Yu BW. Mechanism of chronic postoperative pain and perioperative prevention. Chin J Pain Med. 2018;5:367\u201372. https:\/\/doi.org\/10.3969\/j.issn.1006-9852.2018.05.011.","journal-title":"Chin J Pain Med"},{"key":"1653_CR6","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.2165\/00003495-200565180-00013","volume":"65","author":"D Simpson","year":"2005","unstructured":"Simpson D, Curran MP, Oldfield V, Keating GM. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65:2675\u2013717. https:\/\/doi.org\/10.2165\/00003495-200565180-00013.","journal-title":"Drugs"},{"key":"1653_CR7","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/bja\/63.4.444","volume":"63","author":"JA Wildsmith","year":"1989","unstructured":"Wildsmith JA, Brown DT, Paul D, Johnson S. Structure-activity relationships in differential nerve block at high and low frequency stimulation. Br J Anaesth. 1989;63:444\u201352. https:\/\/doi.org\/10.1093\/bja\/63.4.444.","journal-title":"Br J Anaesth"},{"key":"1653_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1017\/s0265021505000773","volume":"22","author":"A Casati","year":"2005","unstructured":"Casati A, Vinciguerra F, Santorsola R, Aldegheri G, Putzu M, Fanelli G. Sciatic nerve block with 0.5% levobupivacaine, 0.75% levobupivacaine or 0.75% ropivacaine: a double-blind, randomized comparison. Eur J Anaesthesiol. 2005;22:452\u20136. https:\/\/doi.org\/10.1017\/s0265021505000773.","journal-title":"Eur J Anaesthesiol"},{"key":"1653_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4103\/0019-5049.79875","volume":"55","author":"G Kuthiala","year":"2017","unstructured":"Kuthiala G, Chaudhary G. Ropivacaine: a review of its pharmacology and clinical use. Indian J Anaesth. 2017;55:104\u201310. https:\/\/doi.org\/10.4103\/0019-5049.79875.","journal-title":"Indian J Anaesth"},{"key":"1653_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3923\/jpt.2018.37.44","volume":"13","author":"MQ Hui","year":"2018","unstructured":"Hui MQ, Lu WD, Yu WP, Chen T, Gu JL, Cao YX. Pharmacokinetics and toxicity of oily delivery system of ropivacaine via subcutaneous injectionin beagle dogs. J Pharmacol Toxicol. 2018;13:37\u201344. https:\/\/doi.org\/10.3923\/jpt.2018.37.44.","journal-title":"J Pharmacol Toxicol"},{"key":"1653_CR11","first-page":"1","volume":"1","author":"WD Lu","year":"2018","unstructured":"Lu WD, Hui MQ, Chen T, Wang S, Li QQ, Cao L, Cao YX. The pharmacokinetics and analgesic effectof ropivacaine oil solution after subcutaneousInjection to mini-pig operative incision. United J Pharmacol Ther. 2018;1:1\u201310.","journal-title":"United J Pharmacol Ther"},{"key":"1653_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/mus.21284","volume":"40","author":"MF Osuchowski","year":"2009","unstructured":"Osuchowski MF, Teener J, Remick D. Noninvasive model of sciatic nerve conduction in healthy and septic mice: reliability and normative data. Muscle Nerve. 2009;40:610\u20136. https:\/\/doi.org\/10.1002\/mus.21284.","journal-title":"Muscle Nerve"},{"key":"1653_CR13","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1208\/s12248-009-9153-9","volume":"11","author":"SW Larsen","year":"2009","unstructured":"Larsen SW, Larsen C. Critical factors influencing the in vivo performance of long-acting lipophilic solutions impact on in vitro release method design. J Aaps Journal. 2009;11:762\u201370. https:\/\/doi.org\/10.1208\/s12248-009-9153-9.","journal-title":"J Aaps Journal"},{"key":"1653_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5731\/pdajpst.2011.00634","volume":"65","author":"S Nema","year":"2011","unstructured":"Nema S, Brendel RJ. Excipients and their role in approved injectable products: current usage and future directions. PDA J Pharm Sci Technol. 2011;65:287\u2013322. https:\/\/doi.org\/10.5731\/pdajpst.2011.00634.","journal-title":"PDA J Pharm Sci Technol"},{"key":"1653_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.actbio.2017.06.013","volume":"58","author":"H Li","year":"2017","unstructured":"Li H, Liu T, Zhu Y, Fu Q, Wu W, Deng J, et al. An in situ-forming phospholipid-based phase transition gel prolongs the duration of local anesthesia for ropivacaine with minimal toxicity. Acta Biomater. 2017;58:136\u201345. https:\/\/doi.org\/10.1016\/j.actbio.2017.06.013.","journal-title":"Acta Biomater"},{"key":"1653_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/jat.727","volume":"21","author":"KH Diehl","year":"2001","unstructured":"Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, Vidal JM. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol. 2001;21:15\u201323. https:\/\/doi.org\/10.1002\/jat.727.","journal-title":"J Appl Toxicol"},{"key":"1653_CR17","first-page":"24","volume":"1","author":"TJ Gan","year":"2012","unstructured":"Gan TJ. Incorporating a novel local analgesic into an opioid sparing strategy for postsurgical pain. Anesthesiology News. 2012;1:24\u20135.","journal-title":"Anesthesiology News"},{"key":"1653_CR18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.4103\/aer.AER_14_17","volume":"11","author":"S Bhardwaj","year":"2017","unstructured":"Bhardwaj S, Devgan S, Sood D, Katyal S. Comparison of local wound infiltration with ropivacaine alone or ropivacaine plus dexmedetomidine for postoperative pain relief after lower segment cesarean section. Anesth Essays Res. 2017;11:940\u20135. https:\/\/doi.org\/10.4103\/aer.AER_14_17.","journal-title":"Anesth Essays Res"},{"key":"1653_CR19","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/bja\/aet015","volume":"110","author":"JD Griffiths","year":"2013","unstructured":"Griffiths JD, Le NV, Grant S, Bjorksten A, Hebbard P, Royse C. Symptomatic local anaesthetic toxicity and plasma ropivacaine concentrations after transversus abdominis plane block for Caesarean section. Br J Anaesth. 2013;110:996\u20131000. https:\/\/doi.org\/10.1093\/bja\/aet015.","journal-title":"Br J Anaesth"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-022-01653-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-022-01653-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-022-01653-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T17:05:03Z","timestamp":1650560703000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-022-01653-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1653"],"URL":"https:\/\/doi.org\/10.1186\/s12871-022-01653-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-810329\/v1","asserted-by":"object"}]},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"15 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Procedures for all animals in this study were approved by the Institutional Animal Care and Use Committee at Joinn Laboratories (ethic approval ID: ACU13-722), which requires a full compliance with the U.S. Food and Drug Administration\u2019s Good Laboratory Practice (GLP) regulations (21 CFR Part 58), and were performed in strict accordance with recommendations of the Guide to the Care and Use of Laboratory Animals of the National Institutes of Health. Our paper adheres to the ARRIVE guidelines in compliance with BioMed central editorial policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}